The University of Southampton
University of Southampton Institutional Repository

Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression

Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression
Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression

We evaluated early disease progression and its impact on overall survival in previously untreated follicular lymphoma patients in GALLIUM (NCT01332968), and investigated the effect on early disease progression of the 2 randomization arms: obinutuzumab- versus rituximab-based immunochemotherapy. Cause-specific Cox regression was used to estimate the effect of treatment on the risk of disease progression or death due to disease progression within 24 months of randomization and to analyze overall survival in patients with or without disease progression after 24 months. Mortality in both groups was analyzed 6, 12, and 18 months post-randomization (median follow-up, 41 months). Fewer early disease progression events occurred in obinutuzumab (57/601) versus rituximab (98/601) immunochemotherapy patients, with an average risk reduction of 46.0% (95% CI: 25.0-61.1%; cumulative incidence rate 10.1% versus 17.4%). At a median post-progression follow-up of 22.6 months, risk of mortality increased markedly following a progression event (HR of time-varying progression status, 25.5 [95% CI: 16.2-40.3]). Mortality risk was higher the earlier patients progressed within the first 24 months. Age-adjusted HR for overall survival after 24 months in surviving patients with disease progression versus those without was 12.2 (95% CI: 5.6-26.5). Post-progression survival was similar by treatment arm. In conclusion, obinutuzumab plus chemotherapy was associated with a marked reduction in the rate of early disease progression events relative to rituximab plus chemotherapy. Early disease progression in patients with follicular lymphoma was associated with poor prognosis, with mortality risk higher after earlier progression. Survival post-progression did not seem to be influenced by treatment arm. .

Journal Article
0390-6078
1202-1208
Seymour, John F.
1f4d9aba-841a-40ec-a758-80d6f81dc376
Marcus, Robert
a16601ff-650d-473e-a0ff-81558e16cef5
Davies, Andrew
0fe6a40a-10d1-4ade-a7e6-d1dceb2470af
Gallop-Evans, Eve
aebca187-e82a-40c0-9680-f23c658b00a3
Grigg, Andrew
ddb9b8f3-2c64-45bf-ae12-f00b6119e5e0
Haynes, Andrew
cb199dbd-1910-4bcb-b911-79cb74adb701
Herold, Michael
be78b4e3-e3b0-4a4f-9ba5-f5fb6218ac83
Illmer, Thomas
e828bc6b-d94f-4469-9b7c-4aca96138714
Nilsson-Ehle, Herman
8e7af937-2871-4d04-98b0-4e7536bbcc6f
Sökler, Martin
01331b6e-b3fe-4b6b-a167-c2af2bcd361b
Dünzinger, Ulrich
a0e0881f-f30d-48b0-9e09-9cd4e5573bc8
Nielsen, Tina
6800997e-c4a1-4fa5-b90c-0aae00f6fe68
Launonen, Aino
f3d1fab8-bbf2-4bbe-9216-3dfe687ecf79
Hiddemann, Wolfgang
0710f0bd-14f1-4840-9abd-2349f69e8677
Seymour, John F.
1f4d9aba-841a-40ec-a758-80d6f81dc376
Marcus, Robert
a16601ff-650d-473e-a0ff-81558e16cef5
Davies, Andrew
0fe6a40a-10d1-4ade-a7e6-d1dceb2470af
Gallop-Evans, Eve
aebca187-e82a-40c0-9680-f23c658b00a3
Grigg, Andrew
ddb9b8f3-2c64-45bf-ae12-f00b6119e5e0
Haynes, Andrew
cb199dbd-1910-4bcb-b911-79cb74adb701
Herold, Michael
be78b4e3-e3b0-4a4f-9ba5-f5fb6218ac83
Illmer, Thomas
e828bc6b-d94f-4469-9b7c-4aca96138714
Nilsson-Ehle, Herman
8e7af937-2871-4d04-98b0-4e7536bbcc6f
Sökler, Martin
01331b6e-b3fe-4b6b-a167-c2af2bcd361b
Dünzinger, Ulrich
a0e0881f-f30d-48b0-9e09-9cd4e5573bc8
Nielsen, Tina
6800997e-c4a1-4fa5-b90c-0aae00f6fe68
Launonen, Aino
f3d1fab8-bbf2-4bbe-9216-3dfe687ecf79
Hiddemann, Wolfgang
0710f0bd-14f1-4840-9abd-2349f69e8677

Seymour, John F., Marcus, Robert, Davies, Andrew, Gallop-Evans, Eve, Grigg, Andrew, Haynes, Andrew, Herold, Michael, Illmer, Thomas, Nilsson-Ehle, Herman, Sökler, Martin, Dünzinger, Ulrich, Nielsen, Tina, Launonen, Aino and Hiddemann, Wolfgang (2019) Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression. Haematologica, 104 (6), 1202-1208. (doi:10.3324/haematol.2018.209015).

Record type: Article

Abstract

We evaluated early disease progression and its impact on overall survival in previously untreated follicular lymphoma patients in GALLIUM (NCT01332968), and investigated the effect on early disease progression of the 2 randomization arms: obinutuzumab- versus rituximab-based immunochemotherapy. Cause-specific Cox regression was used to estimate the effect of treatment on the risk of disease progression or death due to disease progression within 24 months of randomization and to analyze overall survival in patients with or without disease progression after 24 months. Mortality in both groups was analyzed 6, 12, and 18 months post-randomization (median follow-up, 41 months). Fewer early disease progression events occurred in obinutuzumab (57/601) versus rituximab (98/601) immunochemotherapy patients, with an average risk reduction of 46.0% (95% CI: 25.0-61.1%; cumulative incidence rate 10.1% versus 17.4%). At a median post-progression follow-up of 22.6 months, risk of mortality increased markedly following a progression event (HR of time-varying progression status, 25.5 [95% CI: 16.2-40.3]). Mortality risk was higher the earlier patients progressed within the first 24 months. Age-adjusted HR for overall survival after 24 months in surviving patients with disease progression versus those without was 12.2 (95% CI: 5.6-26.5). Post-progression survival was similar by treatment arm. In conclusion, obinutuzumab plus chemotherapy was associated with a marked reduction in the rate of early disease progression events relative to rituximab plus chemotherapy. Early disease progression in patients with follicular lymphoma was associated with poor prognosis, with mortality risk higher after earlier progression. Survival post-progression did not seem to be influenced by treatment arm. .

Text
DV-HEM58107_Gallium_POD24_Haematologica_07Dec18 - Accepted Manuscript
Download (577kB)

More information

Accepted/In Press date: 17 December 2018
e-pub ahead of print date: 20 December 2018
Published date: June 2019
Keywords: Journal Article

Identifiers

Local EPrints ID: 427237
URI: http://eprints.soton.ac.uk/id/eprint/427237
ISSN: 0390-6078
PURE UUID: 1f3cf3b9-4c90-4fac-9560-6f725e5790df
ORCID for Andrew Davies: ORCID iD orcid.org/0000-0002-7517-6938

Catalogue record

Date deposited: 09 Jan 2019 17:30
Last modified: 16 Mar 2024 03:58

Export record

Altmetrics

Contributors

Author: John F. Seymour
Author: Robert Marcus
Author: Andrew Davies ORCID iD
Author: Eve Gallop-Evans
Author: Andrew Grigg
Author: Andrew Haynes
Author: Michael Herold
Author: Thomas Illmer
Author: Herman Nilsson-Ehle
Author: Martin Sökler
Author: Ulrich Dünzinger
Author: Tina Nielsen
Author: Aino Launonen
Author: Wolfgang Hiddemann

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×